key: cord-0840640-z6b575jp
authors: Gandjour, A.
title: The Clinical and Economic Value of a Successful Shutdown During the SARS-CoV-2 Pandemic in Germany
date: 2020-05-19
journal: nan
DOI: 10.1101/2020.05.12.20098996
sha: 5e7349b90618a4f36e6dffe142cab61a395b22f1
doc_id: 840640
cord_uid: z6b575jp

Background and aim: Given a potential surge of COVID-19 cases in Germany, the federal government and the federal states have ordered a shutdown of businesses and social activities. An important purpose of the shutdown is to avoid overstretching intensive care unit (ICU) capacity (flattening the curve). The aim of this study was to determine the clinical and economic value of a successful shutdown. Methods: In the base case, the study compared a successful shutdown to a worst-case scenario with no ICU capacity left to treat COVID-19 patients. To this end, a decision model was developed using, e.g., information on age-specific fatality rates, ICU outcomes, and the herd protection threshold. The value of an additional life year was borrowed from new, innovative oncological drugs, as cancer reflects a condition with a similar morbidity and mortality burden in the general population in the short-term. Results: A successful shutdown is projected to yield an average gain between 0.02 and 0.08 life years (0.3 to 1.0 months) per capita in the German population. The corresponding economic value ranges between 2147 and 8056 euros per capita or, extrapolated to the total population, 5% to 19% of the gross domestic product in 2019. Nevertheless, if herd immunity is achieved through natural infection, even a shutdown that is successful in flattening the curve is expected to yield a loss of 0.40 life years per capita compared to the situation before the pandemic. Conclusion: A successful shutdown is forecasted to yield a considerable gain in life years in the German population. Nevertheless, questions around the affordability and underfunding of other parts of the healthcare system emerge.

'Flattening the curve' may thus buy time to expand health and intensive care capacities as well as to develop and test new vaccines, monoclonal antibodies, or drugs. The process of developing a vaccine and obtaining market approval has been estimated to take approximately 12 to 18 months (WSJ 2020). Moreover, there is a "race" to find COVID-19 treatments by repurposing drugs that are already approved for other diseases and have acceptable safety profiles (Kupferschmidt 2020) . Given the necessary time lag, 'flattening the curve' may only be able to halt the pandemic by achieving herd immunity through natural infection.

An alternative strategy to 'flattening the curve', which has also received notable attention in recent weeks, is stopping or 'squashing' the curve. This strategy aims at suppressing the pandemic, by bringing the reproduction number to less than 1, until an effective vaccine or treatment becomes available. Obviously, it requires a more rigid government intervention than 'flattening the curve', at least in the short term.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 19, 2020. . https://doi.org/10.1101/2020.05.12.20098996 doi: medRxiv preprint 3 As a result of the drastic restrictions on everyday life imposed by the German authorities, domestic demand is being hit by a combined supply and demand shock (van Harn 2020). The German ifo Institute estimates that prolonging the German shutdown for one additional week results in costs of 25 to 57 billion euros and causes a reduction of the gross domestic product (GDP) of 0.7 to 1.6 percentage points (Dorn 2020) .

Trade-offs between protecting lives and revitalizing the economy thus seem inevitable.

Therefore, the purpose of this study is to determine the clinical and economic value of minimizing the number of life years lost due to the SARS-CoV-2 pandemic in Germany.

While I will refer specifically to a 'shutdown' in the following, COVID-19 containment measures go beyond a shutdown and include tracking, testing, public mask-wearing, and other measures that are largely independent of a shutdown. The study takes an ex-ante viewpoint, i.e., before a potential surge of COVID-19 cases possibly overstretches ICU capacity. I determine the clinical and economic value both of 'squashing' and 'flattening' the curve, thus assuming, respectively, that new vaccines or treatments will and will not be available before herd immunity through national infection is achieved. As the study does not analyze specific subgroups of the population but the population in aggregate, minimizing the number of life years lost by 'flattening the curve' effectively translates into minimizing lives lost by minimizing the CFR (when 'squashing the curve', it is possible to minimize life years or lives lost by reducing the incidence of SARS-CoV-2 infections). Moreover, when 'flattening the curve' the economic value of minimizing the number of life years lost corresponds to the maximum economic value of a shutdown that is 100% effective at preventing an overstretch of ICU capacity (because a successful shutdown leads to a minimization of lives lost and life years lost). Hence, under a scenario in which the spread of the virus in the population is unavoidable, a successful shutdown presents the best-case scenario.

As a comparator of a shutdown that is successful in 'flattening' or 'squashing" the curve, I considered a scenario with no ICU capacity left to treat COVID-19 patients.

While this scenario presents an extreme (worst) case, it is appropriate to determine the maximum health benefit of a successful shutdown and calculate the maximum economic value of the shutdown. This allows a comparison with actual and expected public . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 19, 2020. . https://doi.org/10.1101/2020.05. 12.20098996 doi: medRxiv preprint 4 spending during and after the SARS-CoV-2 pandemic in Germany. In addition, for 'flattening the curve' the study considers alternative scenarios with ICU capacity being exceeded by varying amounts. These scenarios help assess the maximum economic value of freeing up or adding ICU capacity while 'flattening the curve'.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 19, 2020 -table model   As a basis for the calculation of life years saved by a successful shutdown and alternative scenarios, I developed a life-table model to summarize the age-specific mortality impact of the SARS-CoV-2 pandemic. In order to account for an increase in mortality due to the SARS-CoV-2 pandemic, I used two methodological approaches. In the first, I multiplied the probabilities of survival given exposure to SARS-CoV-2 with the probabilities of survival from competing causes of death. This calculation relies on an independence assumption, implying that individuals not dying from COVID 19 have the same probability of death as all individuals before the rise of the pandemic. Given that patients who die from COVID 19 tend to have more comorbidities (Wu 2020), I assumed a harvesting effect in the second approach. This approach presumes that those who die from COVID-19 are sicker and "would have died anyway" (cf. Financial Times 2020). In this scenario, I assumed for age groups with excess mortality associated with COVID-19 (the difference between observed and noncrisis mortality rates) that except for COVID-19, there are no other causes of death in the forthcoming 12 months. This is compatible with the notion that COVID-19 may be "the cause of all fatalities" (Centre for Evidence-Based Medicine 2020). This implies that those who do not die from COVID-19 despite being infected represent a healthier population. In either approach, the population that is not infected (which is one minus the proportion of the population that has recovered from COVID-19 to provide herd immunity) is assumed to remain at risk for competing causes of death.

Assuming that deaths occur, on average, halfway at each age, I took the average of the number of people at the start and end of the age interval to estimate state membership (Barendregt 2009 ). To calculate life-expectancy gains of a successful shutdown and alternative scenarios, I determined the cumulative probability of an individual at age i of surviving until age j (i.e., the product of age-specific survival probabilities up to age j) as obtained from the life table. I took the sum over all ages j, thus obtaining the remaining life expectancy of an individual at age i. The remaining life expectancy needs to be interpreted as a hypothetical measure that summarizes the age-specific death rates in a population exposed to SARS-CoV-2. I determined the difference between a successful shutdown (and alternative scenarios) and no intervention, thus obtaining the incremental number of life years gained. To account for the age distribution . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 19, 2020. . https://doi.org/10.1101/2020.05.12.20098996 doi: medRxiv preprint 6 of the population, I weighted age-specific life-expectancy gains by age-specific population sizes. I performed all calculations for men and women separately and then aggregated the results.

As updating the probabilities of survival in the life table and calculating the remaining life expectancy yields the remaining life expectancy (and associated loss) with lifelong exposure to SARS-CoV-2 (as opposed to a one-time exposure), it was adjusted accordingly. To this end, I distributed the age-and gender-specific loss in life expectancy over the age-specific remaining lifetime before the pandemic by dividing the two variables and then aggregated the resulting figures across age and gender by the corresponding population sizes. I did not discount health benefits because the reported survival benefits from cancer treatment (see below), which are used to determine the economic value of a life year, were undiscounted as well.

In the scenarios with insufficient ICU capacity, all patients barred from admission to the ICU were assumed to die. However, even with sufficient ICU capacity patients face a probability of death both in the ICU and post discharge. The resulting mortality is considered to be unavoidable (with currently available treatments) and, hence, cancels out in the estimate of life years associated with a shutdown that is successful in 'flattening the curve' versus no intervention. More specifically, I assumed that fatality in the ICU is already reflected in the CFR reported for Germany before the occurrence of the pandemic peak. Hence, I only added the fatality one year after discharge (multiplied by the proportion of the population admitted to the ICU) to the currently reported population CFR.

In addition, I considered 4 scenarios with varying degrees of insufficient ICU capacity.

To determine the corresponding loss of life years compared to the situation before the pandemic, I calculated a weighted-average loss of life years of each scenario, with weights reflecting the proportions of patients admitted to the ICU and patients refused admittance. These weights were multiplied by the average loss of life years of the patients admitted and refused admittance. Of note, the excess demand for ICU beds available during the crisis refers to the average demand and not the peak demand at the height of the SARS-CoV-2 pandemic.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 19, 2020. .

Finally, I analyzed a scenario based on the idea of 'squashing the curve'. To this end, I applied the mortality data before the pandemic and calculated the difference in life years gained compared to no intervention. The calculation is equivalent to adding the absolute loss of life years associated with a shutdown that is successful in 'flattening the curve' to the gain in life years of the latter compared to no intervention.

In one-way deterministic analyses, I assessed parameter uncertainty by varying the input parameters that are subject to variation one at a time.

Given the absence of an official cost-effectiveness threshold and reliable data on the health care trajectories of COVID-19 patients in Germany, which could help derive the willingness to pay for an effective shutdown (cf. Gandjour 2020), I borrowed the willingness to pay from the cost-effectiveness ratio of new, innovative cancer drugs. In Germany, the prices of new, innovative drugs are subject to negotiation between manufacturers and representatives of statutory health insurance (SHI). Negotiated list prices hold for all German citizens, including those covered by private insurance. From the perspective of an average citizen, notable similarities between COVID-19 and cancer exist. First, with regard to the next 12 months (the earliest point in time a vaccine is expected to become available), the expected death toll from cancer will fall in a similar range (approximately 223,000 people in Germany died of cancer in 2016 (Robert Koch Institut 2016)). Hence, from the perspective of an average citizen, deaths from cancer will not be more remote than deaths from COVID-19. A similar conclusion would be drawn when analyzing excess mortality, which is absent in most age groups. Therefore, at the population level, both diseases seem to pose a similar threat to life within the next 12 months.

Moreover, from the perspective of an average citizen, the probability of being affected by a severe disease in the next 12 months is also comparable. Approximately 1.6 million Germans suffer from cancer (diagnosed within the past 5 years), while the number . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 19, 2020. . https://doi.org/10.1101/2020.05.12.20098996 doi: medRxiv preprint 8 of COVID-19 cases expected to require ICU treatment 1 within the next 12 months under 'flattening the curve' is 3.7 million (bearing in mind that this is likely to present an overestimate due to a high number of undetected cases (Streeck 2020) ). In addition, for both diseases, the vast majority of people is not expected to suffer. 2 Notably, the contingent-valuation method, which asks members of a representative sample of the population for their hypothetical willingness to pay, requires educating participants about epidemiological concepts, such as excess mortality and competing diseases, which are key for understanding the mortality burden in COVID-19. That is, a survey cannot simply focus on COVID-19 and ignore concomitant diseases. However, even if this were feasible, contingent-valuation techniques, such as discrete choice experiments, have not found their way into the official drug assessment and pricing policy of pharmaceuticals in Germany, despite being tested over many years and even in a perhaps less controversial role, i.e., weighting the adverse events and desirable outcomes of drugs. Therefore, it seems unlikely that a population survey using a discrete choice experiment or an alternative contingent-valuation technique could influence policymaking in this crisis. Furthermore, politicians who are involved in current policymaking accept the negotiation outcomes for pharmaceuticals (otherwise, the negotiation process would be on the political agenda). Hence, politicians may also have a more favorable view of using the negotiation results for the purpose of putting a price tag on the life years gained from the shutdown. 1 The number of COVID-19 hospitalizations is less reliable because it includes quarantine as an indication. 2 This framework resembles that of Dworkin's Theory of Equality (1981), in which an "average member of the community" (ibid., p. 297) behind a 'thin' veil of ignorance does not know which handicaps he will eventually develop but does know the probability of becoming handicapped. Using this framework does not necessitate, however, to incorporate all constituents of Dworkin's Theory of Equality and to accept the resource allocation principles inferred from it.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 19, 2020. Given that the economic value would need to be compared against the direct (non-)medical costs to treat COVID-19 patients as well as the indirect costs secondary to productivity loss, the perspective of the analysis is inherently societal. Given the societal perspective, I made the simplifying assumption that cancer drug costs from the SHI perspective are equal to the drug costs from a societal perspective. Strictly speaking, this does not hold particularly if manufacturers reside inside Germany. In the latter case, drug expenditures need to be adjusted for producer surplus, as it presents a gain in societal welfare (Garrison 2010) .

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 19, 2020. . https://doi.org/10.1101/2020.05.12.20098996 doi: medRxiv preprint

The model input data are listed in Table 1. I used the most recent period life table of the German Federal Office of Statistics (2019), which incorporates the mortality data by age and gender up to the age of 100 years (data are from 2016 to 2018). In addition, I used data from the German Federal Office of Statistics on the population size by age and gender up to the age of 100 years.

Data on overall case fatality in the German population and in 6 age groups as well as data on ICU fatality were obtained from the Robert Koch Institut (2020). Data on 155 cases could not be classified by age. In a sensitivity analysis I applied the CFR from a recent empirical study on 1000 people in one German district (Heinsberg), which shows a rate of just 0.36% (Streeck 2020 ) and thus suggests a high number of undetected cases in the national data. I adjusted the percentage of patients admitted to the ICU accordingly because a lower CFR also implies a lower percentage of cases admitted to the ICU. The base-case admission rate to the ICU is 6.4% (Robert Koch Institut 2020).

In Germany, the fatality rate in the ICU for all COVID-19 patients is 28% (Robert Koch Institut 2020). Sixty-nine percent of patients currently being treated in the ICU due to COVID-19 receive mechanical ventilation (Robert Koch Institut 2020). Given that ICU survivors face an increased probability of death after discharge, I added the difference between the ICU fatality rate and the postdischarge fatality rate to the ICU fatality rate.

Data were obtained from a meta-analysis of international studies on critically ill patients treated with prolonged mechanical ventilation (Damuth 2015) . In this study, the pooled mortality at hospital discharge was 29% and thus is close to the rate reported for COVID-19 ICU patients. The one-year mortality increased to 59%. Nevertheless, the meta-analysis may be criticized because the data are relatively old (studies were published before November 2013) and heterogeneous in terms of outcomes. For example, the United States (U.S.) showed a significantly higher mortality than the rest of the world. Nevertheless, the fact that the mortality at hospital discharge exactly matches the current data for COVID-19 patients seems to be a convincing argument in favor of incorporating this data from the meta-analysis. In a sensitivity analysis, I incorporated . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 19, 2020. . https://doi.org/10.1101/2020.05. 12.20098996 doi: medRxiv preprint the one-year CFRs reported for the U.S. and the rest of the countries (73% and 47%, respectively).

A considerable increase in mortality after hospital discharge was confirmed in a recently published study on 21 COVID-19 patients admitted to the ICU at a single center in Washington State (Arentz 2020) . In this study CFR was 52% at hospital discharge and increased to 67% 12 days after admission. In a sensitivity analysis, I incorporated the CFR on the ICU from this study as an upper bound. As the lower bound, I used data from an analysis of the European Surveillance System (TESSy) database including 13,368 patients admitted to the ICU with laboratory confirmed influenza virus infection between 2009 and 2017 (Adlhoch 2019). In this sample, 83% of patients were ventilated, which is higher than the current rate in Germany (69%). The CFR was 21%, based on a median age of 59 years of admitted patients. Hence, the median age was lower than the median age of death (82 years) currently reported for Germany (Robert Koch Institut 2020). Nevertheless, it needs to be considered that in the SARS-CoV-2 pandemic a portion of the elderly patient population is less likely to be admitted to the ICU and may die, e.g., in nursing homes. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 19, 2020. . https://doi.org/10.1101/2020.05.12.20098996 doi: medRxiv preprint

Based on the independence assumption of mortality rates, a shutdown that is successful in 'flattening the curve' is projected to result in 1.6 million lives being saved and 3.3 million life years being gained in the German population at the time of herd immunity through natural infection (versus no intervention). On a per-capita basis, a successful shutdown is projected to yield an average gain of 0.058 life years (0.69 months). This estimate is subject to nonnegligible uncertainty, however. As shown in the sensitivity analysis (see Figure 1 ), a lower CFR in the population or a higher CFR in the ICU or post discharge reduce the health benefit by one to two thirds. The health benefits of a shutdown also diminish when ICU capacity is exceeded. As shown in Table 2 , if the shutdown does not turn out to be successful, exceeding ICU capacity by 50% could more than halve the gain in life years.

Nevertheless, at the time of herd immunity, even a shutdown that is successful in 'flat- 

The economic value of a shutdown that is successful in 'flattening the curve', based on a per-capita gain of 0.058 life years, is approximately €5838 per capita (see Table 2 ) or, extrapolated to the total population, 14% of Germany's GDP in 2019. Using lower and higher estimates based on the sensitivity analysis, the economic value ranges between 5% and 19% of the GDP. The economic value of 'squashing the curve' even . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 19, 2020. . https://doi.org/10.1101/2020.05. 12.20098996 doi: medRxiv preprint amounts to 118% of the GDP. It is highly sensitivity to changes in CFR, however: A CFR of 0.36% (Streeck 2020) reduces the economic value to 24%.

The product of the probabilities of ICU admission and death cannot exceed the CFR in the general population. In fact, given that a portion of deaths occur outside the ICU even with sufficient ICU capacity (e.g., in nursing homes), the product needs to be smaller. This was confirmed (3.7% < 4.3%).

Furthermore, I performed a back-of-the-envelope calculation to verify the health benefits of a shutdown that is successful in 'squashing the curve' versus no intervention. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 19, 2020. The relatively small loss in life years obtained by assuming that individuals who die from COVID-19 are generally sicker, was indirectly confirmed in another modeling study based on global data (Hanlon 2020) . This study showed that explicitly accounting for the various comorbidities associated with COVID-19 "did not drastically impact" the years of life lost due to death from COVID-19.

In addition to comparing the cases of a successful shutdown and no intervention, which forms the base case for the calculation of the maximum monetary value, I analyzed different scenarios with ICU capacity being exceeded to varying degrees. The likelihood of these scenarios depends on the spread of SARS-CoV-2 if the shutdown is not completely effective. Data from 2010/11 indicate that Germany has the highest number of intensive care plus immediate care unit beds on a per-capita basis in Europe (Rhodes 2012 ). Germany's leading position in terms of the number of ICU beds was recently confirmed in a report by the Organisation for Economic Co-operation and Development (OECD 2020). The currently available number of ICU beds is approximately 40,000, with 15,000 to 20,000 being unused (Rheinische Post 2020). Based on an estimated length of stay of 14 days for COVID-19 patients (KSTA 2020, SWR 2020)), ICU capacity will be exceeded, however, when the daily incidence of COVID-19 cases surpasses approximately 16,000 (disregarding a potentially lower admission rate due to a high number of undetected COVID-19 cases).

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 19, 2020. . https://doi.org/10.1101/2020.05.12.20098996 doi: medRxiv preprint As a word of caution, given the time constraints and the ongoing inflow of new information on the SARS-CoV-2 pandemic while conducting the study and writing this manuscript, which made it pertinent to continuously update the projections, this modeling study has several caveats as discussed below. Given the clear direction of its results, however, it could still provide important guidance for policymakers, which is outlined further below.

First, there are reasons why the base case overestimates the projected health benefits of a shutdown and the corresponding monetary value. Some of these reasons were already described in the sensitivity analysis and include an underestimate of CFR due to a possible time lag in the occurrence of deaths. Furthermore, the study does not consider the deaths and loss of health-related quality of life associated with the shutdown and social distancing, e.g., due to depressive or anxiety disorders, suicides, unemployment, domestic violence, and fewer emergency and physician visits for unrelated medical conditions. In addition, ICU survivors may suffer from a loss of quality of life (Needham 2013) . Furthermore, unaffected individuals may experience a loss of personal freedom (Abele-Brehm 2020) and autonomy.

On the other hand, there are reasons to believe that the economic value may be un- is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 19, 2020. . https://doi.org/10.1101/2020.05. 12.20098996 doi: medRxiv preprint treatment for more than one year. On the other hand, the estimate is too high because the survival benefit is underestimated because it is confined to the trial period, which typically may not be longer than a year. Again, some of the biases may cancel out.

Furthermore, it may be argued that treatments for conditions more closely related to COVID-19 would provide a more accurate estimate for the economic value. This may include treatments for other viral diseases such as SARS-CoV-1, influenza, or Ebola.

Even greater similarity could be obtained by restricting conditions to those that have a similar route of transmission (airborne droplets), CFR, and basic reproduction number (the average number of secondary infections due to a single primary infected person; it may reflect a sense of urgency). Nevertheless, the search for a better match may not turn out to be successful. It may also be hampered by the fact that an ideal economic valuation of 'flattening' or 'squashing' the curve would reflect recently set prices and not the prices of drugs that were launched, for example, more than a decade ago.

Using the prices of new, innovative cancer medications as a benchmark also provides an opportunity to check the appropriateness of current cancer prices themselves. If the economic value of 'flattening' or 'squashing' the curve as determined in this study were considered to be low, then to be consistent, the prices of new cancer drugs would equally deserve a price premium. This implication, however, is contradictory to the present situation, as the pressure to save on health care costs will increase as a con- Given the unprecedented economic value as a share of GDP estimated in this study, the corona crisis also leads to new challenges for economic evaluations in health care and public health. Perhaps the most similar dilemma has arisen surrounding one-off treatments (cures) for genetic disorders. One-off payments for these therapies similarly raise affordability issues even in view of acceptable cost-effectiveness ratios (Towse . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Acknowledging this negative feedback loop on the health care system, the way to think about the problem at hand may be in terms of a constrained resource allocation problem, with minimization of life years lost as the objective function and cost-effectiveness ratio, percentage of income spent on health, and ICU capacity as three constraints.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 19, 2020. . https://doi.org/10.1101/2020.05. 12.20098996 doi: medRxiv preprint Ethical values were already incorporated in the economic value but reappear as an additional constraint when comparing the different exit strategies for lifting social isolation measures. In fact, if agreement on the maximum economic value were reached, the next step would involve assessing the cost-effectiveness of different exit strategies.

For the purpose of minimizing the number of life years lost, this would require calculating the degree of excess demand for ICU capacity and the resulting death toll in the absence of intensive care for each exit strategy.

For data collection in the forthcoming months of the crisis, policymakers should pay particular attention to mortality data, as the clinical and economic values forecasted in this study were shown to be particularly sensitive to these data.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 19, 2020. . https://doi.org/10.1101/2020.05.12.20098996 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 19, 2020. Herd protection threshold 0.70 (0.60 -0.70) Kwok 2020 ICU = intensive care unit, CFR = case fatality rate . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 19, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 19, 2020. . https://doi.org/10.1101/2020.05.12.20098996 doi: medRxiv preprint

Die Bekämpfung der Coronavirus-Pandemie tragfähig gestalten: Empfehlungen für eine flexible, risikoadaptierte Strategie

Determinants of Fatal Outcome in Patients Admitted to Intensive Care Units With Influenza, European Union

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

The half-cycle correction: banish rather than explain it

Global Covid-19 Case Fatality Rates

Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis

Ein freier Markt garantiert keine Gesundheitsversorgung. Die Zeit

Die volkswirtschaftlichen Kosten des Corona-Shutdown für Deutschland

What is equality? Part 2: Equality of resources

Fair Allocation of Scarce Medical Resources in the Time of Covid-19

Wiesbaden: Federal Office of Statistics

Federal Office of Statistics

Wiesbaden: Federal Office of Statistics

Pressemitteilung Nr. N 011 vom 13

UK strategy likely to cause 35,000-70,000 excess deaths, says study

A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency

Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II

Analyse der AMNOG-Erstattungsbeträge im europäischen Preisumfeld. Gesundh Ökon Qual Manag

COVID-19 -exploring the implications of long-term condition type and extent of multimorbidity on years of life lost: a modelling study [version 1; peer review: awaiting peer review

Pricing in the market for anticancer drugs

Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures

Grippe oder Covid-19? Diese Symptome sprechen für eine Infektion mit dem Coronavirus

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Race to find COVID-19 treatments accelerates

Herd immunity -estimating the level required to halt the COVID-19 epidemics in affected countries

One year outcomes in patients with acute lung injury randomised to initial trophic or full enteral feeding: prospective follow-up of EDEN randomised trial

Beyond Containment: Health systems responses to COVID-19 in the OECD

Kliniken verfügen nun über 40.000 Intensivbetten

The variability of critical care bed numbers in Europe

Can you put a price on COVID-19 options? Experts weigh lives versus economics

Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event

Coronavirus -so werden Covid-19-Patienten auf Intensivstation behandelt

CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment? Value Health

COVID-19 pushes Germany into recession

Human Testing Begins Earlier Than Expected For U.S. Coronavirus Vaccine

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a

Cases From the Chinese Center for Disease Control and Prevention

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted